Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $23.0752W HIGH $72.64
Volume
855.45 K
Value Traded
47.83 M
Short % Float
13.63%
Days to Cover
7.9
+3.48%Week
+10.31%1 Month
-18.04%3 Month
+80.57%6 Month
+38.48%5 Year
+38.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.69 B
EPS (TTM)
-3.01
P/E Ratio
-
Ent. Value
2.21 B
Total Shares
48.16 M
Float Shares
31.44 M
Insiders
36.68%
Institutions
84.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MBX Catalyst Timeline
Dated clinical, regulatory and corporate events for MBX Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MBX Biosciences, Inc.
151Total events
9Upcoming
20Tier-1 (high impact)
2023 to 2029Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
MBX Biosciences reports third quarter 2026 financial results and corporate highlights
●Poster PresentationPresentation
Poster presentation of synthetic vaginal matrix for HPV assay validation at IPVS 2026
HPV / cervical cancer screeningsource ↗
●ATM ProgramCorporate
Net proceeds of $97.6 million from sale of common stock under ATM sales agreement
●R&D DayPresentation
Microbix presenting at Muskoka Capital Event with 18 one-on-one investor meetings
▲Manufacturing MilestoneCMC / Inspection
Microbix completes formal supplier qualification for five major IVD manufacturers
●Equity OfferingCorporate
Inducement equity award granted to Jeff Held (89,250 options and 19,125 RSUs)
▲First Patient DosedCanvuparatideTrial
First patient dosed in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide
chronic hypoparathyroidismsource ↗
▲Trial InitiationCanvuparatideTrial
Initiation of pivotal Phase 3 oPTimize trial
chronic hypoparathyroidismsource ↗
▲Development Candidate NominationPreclinical
Nomination of MBX 6180 as GLP-1/GIP/GCG triple agonist prodrug development candidate
obesitysource ↗
▲First Patient DosedCanvuparatideTrial
First patient dosed in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide
chronic hypoparathyroidismsource ↗
▲Trial InitiationCanvuparatideTrial
Pivotal Phase 3 oPTimize trial of canvuparatide underway
chronic hypoparathyroidismsource ↗
●Management ChangeCorporate
Steve Hoerter appointed Chairman and CEO, John Smither appointed CFO
◆Development Candidate NominationPreclinical
Nomination of GLP-1/GIP/GCGR triple agonist candidate for obesity
obesitysource ↗
●Trial InitiationCanvuparatideTrial
Pivotal Phase 3 oPTimize trial of canvuparatide underway
chronic hypoparathyroidismsource ↗
●ATM ProgramCorporate
$97.6 million net proceeds from sale of common stock under ATM sales agreement
◆Oral PresentationCanvuparatidePresentation
Full results from 12-week Avail Phase 2 trial of once-weekly canvuparatide presented at ENDO 2026
chronic hypoparathyroidismsource ↗
◆Oral PresentationCanvuparatidePresentation
One-year open-label extension data from Phase 2 trial of once-weekly canvuparatide presented at 3rd Parathyroid Summit during ENDO 2026
chronic hypoparathyroidismsource ↗
◆R&D DayCanvuparatidePresentation
Virtual investor event to discuss canvuparatide presentations at ENDO 2026
chronic hypoparathyroidismsource ↗
▲Full ResultsCanvuparatideClinical Data
Full results from 12-week Avail Phase 2 trial announced
chronic hypoparathyroidismsource ↗
▲Oral PresentationCanvuparatidePresentation
Full Phase 2 and one-year OLE data presented at ENDO 2026
chronic hypoparathyroidismsource ↗
◆R&D DayPresentation
MBX Biosciences to host Obesity Day to discuss expanding obesity portfolio
obesitysource ↗
▲Topline ReadoutClinical Data
Preliminary blinded Phase 1 data for MBX 4291: mean weight loss 7% at 8 weeks in first MAD Part B cohort
obesitysource ↗
▲Development Candidate NominationPreclinical
MBX 5765 nominated as amycretin prodrug development candidate
obesitysource ↗
▲Primary Endpoint MetimapextideClinical Data
Imapextide achieved proof of concept in PBH: positive Phase 2a STEADI trial results
post-bariatric hypoglycemia (PBH)source ↗
▼Program DiscontinuationimapextideCorporate
Company will not commit further investment toward Phase 2b trial of imapextide in PBH
post-bariatric hypoglycemia (PBH)source ↗
◆R&D DayPresentation
Obesity Day featuring initial blinded data from MBX 4291 Phase 1 trial
obesitysource ↗
▲Development Candidate NominationPreclinical
Nomination of MBX 5765 as amycretin prodrug development candidate
obesitysource ↗
●Equity OfferingCorporate
Issuance of equity inducement award to new Chief Business Officer Karen Basbaum
◆Topline ReadoutimapextideClinical Data
Phase 2a STEADI trial results for imapextide
post-bariatric hypoglycemiasource ↗
◆Oral PresentationCanvuparatidePresentation
Presentation of full Phase 2 Avail trial results including OLE data at medical conference
hypoparathyroidismsource ↗
◆Development Candidate Nominationamycretin prodrugPreclinical
Nomination of amycretin prodrug development candidate
obesitysource ↗
◆Full ResultsCanvuparatideClinical Data
Full 12-week dataset and one-year follow-up data from Phase 2 Avail trial
hypoparathyroidismsource ↗
▲End Of Phase 2 MeetingCanvuparatideFDA Meeting
End-of-Phase 2 meeting with FDA completed for once-weekly canvuparatide
hypoparathyroidismsource ↗
Past FDA Catalysts and PDUFA Decisions
How MBX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-12 | canvuparatide (MBX 2109) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 16%
Small Cap(rank 111 of 689)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MBX 4291 PeptidesNCT07142707 | Obesity | Phase 1 | RECRUITING | 124 | Oct 30, 2026 | ||||||
| Canvuparatide PeptidesNCT06531941 | Hypoparathyroidism | Phase 3 | ACTIVE NOT_RECRUITING | 220 | May 1, 2028 | ||||||
| MBX 2109 Small MoleculesCompletedNCT06465108 | Hypoparathyroidism | Phase 2 | COMPLETED | 64 | Jun 4, 2025 | ||||||
| MBX 2109 Small MoleculesCompletedNCT06496217 | Renal Impairment | Phase 1 | COMPLETED | 25 | Sep 4, 2025 | ||||||
| MBX 1416 Small MoleculesCompletedNCT06036784 | Postbariatric Hypoglycemia | Phase 2 | COMPLETED | 89 | Dec 5, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every MBX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| canvuparatide Orphan | chronic hypoparathyroidism | Phase 2 | 2026-06-12 | 57% responder rate at one year; 63% of canvuparatide-treated patients achieved the primary composite endpoint at 12 weeks; 31% of placebo-treated patients achieved the primary composite endpoint at 12 weeks (p=0.042); 90% retention rate in the OLE studyRead More | MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hoerter Steven L.Director, Officer (Chairman, President and CEO) | Sell | -4,893 78,045 held | $54.82 | 11/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MBX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8 % (56.9 %) | 367.19 M | 6.65 M |
Ownership Trends
MBX Short Interest
Shares sold short, counted twice a month.
13.63%
Short % of Float
of tradable shares sold short
4.3M
Shares Sold Short
-3.1% vs prior count
7.9 High
Days to Cover
trading days of normal volume to buy every short share back
542.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MBX ranks across every disease it competes in
Competitive Position is a premium feature
See how MBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMBX News
MBXMBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported its third quarter 2026 financial results, highlighting the initiation of the pivotal Phase 3 oPTimize trial for canvuparatide. The company is on track to release unblinded data for MBX 4291 in Q4 2026. With $481.6 million in cash, MBX is well-positioned for future development in obesity and endocrine disorders.
Read more →MBX▲ +5.8%on this news
Microbix Attending & Presenting at IPVS 2026
Microbix Biosystems will present a novel synthetic vaginal matrix at IPVS 2026, aimed at enhancing the validation of HPV molecular assays. The product, developed for self-collected specimens, shows promising results in detecting HPV genotypes. This innovation could facilitate wider adoption of self-collection methods in cervical cancer screening.
Read more →MBX▼ -5.8%on this news
MBX Biosciences to Participate in Upcoming November Investor Conferences
MBX Biosciences has announced its participation in several upcoming investor conferences in November 2026. The events include the Guggenheim 3rd Annual Healthcare Innovation Conference, UBS Global Biopharma Conference, and Jefferies Global Healthcare Conference. Key executives will present and engage in discussions, showcasing the company's focus on precision peptide therapies for endocrine and metabolic disorders.
Read more →MBXMicrobix Making Keynote Presentation at Masters Summit 2026
Microbix Biosystems Inc. will present at the Masters Summit 2026, showcasing its successful implementation of MasterControl's electronic Quality Management System (eQMS). The presentation will detail the challenges and achievements in onboarding the software, which is crucial for becoming a qualified supplier to major life sciences companies. The event will take place in Salt Lake City, Utah, from October 12-15, 2026.
Read more →MBXMicrobix Presenting at Cantech Investment Conference
Microbix Biosystems Inc. will present at the Cantech Investment Conference on October 8, 2026. CEO Cameron Groome will lead the presentation and hold one-on-one meetings with investors. The company, known for its contributions to diagnostic testing and laboratory quality assurance, aims to enhance global health with its innovative products. Microbix's financial performance and product offerings position it as a key player in the diagnostics industry.
Read more →MBX▼ -6.6%on this news
Microbix Presenting at Muskoka Capital Event
Microbix Biosystems Inc. will present at the Muskoka Capital Event from September 25 to 27, 2026. CEO Cameron Groome and Director Pavel Zhelev will hold 18 one-on-one meetings with investors. The company focuses on advancing global health through diagnostic products and has reported revenues of C$18.6 million for fiscal 2025.
Read more →MBXMBX Biosciences to Participate in Upcoming Investor Conferences
MBX Biosciences, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. CEO Steve Hoerter and CMO Sam Azoulay will present at the Morgan Stanley 24th Annual Global Healthcare Conference and the Stifel 2026 Virtual Cardiometabolic Forum. The company aims to showcase its pipeline of precision peptide therapies targeting endocrine and metabolic disorders.
Read more →MBXMicrobix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers
Microbix Biosystems Inc. has achieved formal qualification as a supplier for five of the largest in-vitro diagnostics manufacturers. This qualification allows Microbix to supply critical products, enhancing its business prospects. While it does not guarantee contracts, it positions Microbix favorably for future opportunities in the diagnostics market.
Read more →MBXMBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
MBX Biosciences has appointed Jeff Held as Chief Legal Officer, bringing extensive legal and executive experience from the biotechnology sector. His previous roles include leadership positions at Zenas BioPharma and Deciphera Pharmaceuticals. Held's expertise is anticipated to support MBX's growth and advancement of its precision peptide therapies for endocrine and metabolic disorders.
Read more →MBXMBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
MBX Biosciences has initiated its pivotal Phase 3 oPTimize trial for canvuparatide, a once-weekly treatment for chronic hypoparathyroidism. The trial aims to enroll around 160 adults and follows positive results from the Phase 2 Avail trial. The primary endpoint focuses on achieving normal calcium levels and reducing reliance on vitamin D supplements.
Read more →MBXMBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported its second quarter 2026 financial results, highlighting significant milestones in its pipeline. The company presented positive data for canvuparatide, a potential treatment for chronic hypoparathyroidism, and initiated a Phase 3 trial. Additionally, promising initial data for MBX 4291 supports its development as a once-monthly obesity treatment. The company maintains a strong financial outlook with substantial cash reserves.
Read more →MBX▼ -5.7%on this news
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
MBX Biosciences has announced a leadership transition, appointing Steve Hoerter as CEO and John Smither as CFO. Hoerter succeeds co-founder Kent Hawryluk, who has stepped down. The company aims to continue its growth trajectory and is on track to achieve significant milestones in 2026, including a Phase 3 trial initiation.
Read more →MBXMBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences announced positive one-year data for canvuparatide, a potential treatment for chronic hypoparathyroidism. The open-label extension study showed a 57% responder rate, consistent with previous Phase 2 results. Patients maintained normal serum calcium levels and experienced improved kidney function. The company plans to initiate a Phase 3 trial in Q3 2026.
Read more →MBXMBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
MBX Biosciences will host a virtual investor event on June 12, 2026, to discuss data on once-weekly canvuparatide. Presentations will include one-year open-label extension data and results from the 12-week Phase 2 trial at the ENDO 2026 conference. Notable experts will join the discussion, highlighting the company's advancements in peptide therapies.
Read more →MBXMBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
MBX Biosciences will present at the Jefferies 2026 Global Healthcare Conference in New York City. The presentation is scheduled for June 3, 2026, and will feature insights from CEO Kent Hawryluk and CMO Sam Azoulay. The company focuses on precision peptide therapies for endocrine and metabolic disorders and is advancing its pipeline, including candidates in various development phases.
Read more →MBXMBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences has provided an update on its obesity portfolio, highlighting preliminary Phase 1 data for MBX 4291, which shows a mean weight loss of 7% at 8 weeks. The drug was generally well tolerated, with minimal adverse events reported. The company is also advancing MBX 5765 as a new candidate and remains on track for further data releases in 2026.
Read more →MBX▲ +8.1%on this news· ran to +28% by day 1shared move
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported its first quarter 2026 financial results, highlighting advancements in its pipeline including the Phase 2 trial results of canvuparatide, which has been accepted for oral presentation at the ENDO 2026 annual meeting. The company is on track to initiate a Phase 3 trial of canvuparatide by Q3 2026 and plans to host an Obesity Day to present initial data from the Phase 1 trial of MBX 4291. With a significant cash reserve, MBX appears well positioned for future developments.
Read more →MBX▲ +8.1%on this news· ran to +28% by day 1shared move
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
MBX Biosciences has appointed Mark R. Soued as Chief Commercial Officer, bringing over two decades of experience in commercial leadership within biopharmaceuticals. His expertise includes product launches and market access, which will support MBX's commercialization efforts. The company is advancing a pipeline of precision peptide therapies targeting endocrine and metabolic disorders.
Read more →MBXMBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
MBX Biosciences will host an in-person and virtual Obesity Day on May 11, 2026, to discuss its expanding obesity portfolio. The event will feature experts Richard DiMarchi and Katherine H. Saunders, who will address treatment gaps in obesity. Management will present updates on their Precision Endocrine Peptide platform and ongoing product candidates.
Read more →MBX▼ -5.1%on this news
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MBX Biosciences has granted an equity inducement award to Karen Basbaum as she joins the company as Chief Business Officer. The award includes options for 130,000 shares at an exercise price of $32.29, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting top talent.
Read more →About MBX Biosciences, Inc.
Headquarters11711 N. MERIDIAN STREET, CARMEL, IN, 46032
BIOPHARMAWATCH ELITE
Trade the next MBX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime